convalescent plasma treatment - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.68 [0.41, 1.12]< 10%3 studies (3/-)93.6 %lownot evaluable highcrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.52 [0.29, 0.94]< 10%1 study (1/-)98.5 %lownot evaluable highimportant-
clinical improvement 1.03 [0.71, 1.50]> 144%2 studies (2/-)56.1 %lownot evaluable highimportant-
clinical improvement (28-day) 1.38 [0.73, 2.61]> 10%1 study (1/-)83.9 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.20 [0.87, 1.65]> 10%1 study (1/-)87.0 %lownot evaluable highimportant-
mechanical ventilation 1.50 [0.47, 4.82]< 10%1 study (1/-)24.8 %lownot evaluable highimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.95 [0.44, 2.05]< 170%2 studies (2/-)55.3 %lownot evaluable highimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.